Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

Autor:	AIDS Clinical Trials Group 5211 Team, Gulick, Roy M., Su, Zhaohui, Flexner, Charles, Hughes, Michael D., Skolnik, Paul R., Wilkin, Timothy J., Gross, Robert, Krambrink, Amy, Coakley, Eoin, Greaves, Wayne L., Zolopa, Andrew, Reichman, Richard, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R.
Zdroj:	The Journal of Infectious Diseases, 2007 Jul . 196(2), 304-312.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/30086645 Zobrazit plný text záznamu